In 1995, Yamada and colleagues first proposed a novel low-dose chemotherapy regimen for the treatment of AML, consisting of low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor (G-CSF) priming, referred to as the CAG regimen.3 Here, CSF3 is linked to acute myeloid leukemia.